

February 24, 2022

Contents

Clinical Profile Documentation	2
Problems Tab	2
Labs, Diagnostic Imaging and Other Services	2
Lab, Analytes & Panels Additions	2
Diagnostic Imaging.....	3
Medications	3
Additions	3
Updates	3
Regimens.....	3
Additions	3
Updates.....	4
Removals.....	4
Renames.....	4
Research.....	5
Additions	5
Updates	5
Billing & HCPCS Codes.....	8
Updates.....	8

Clinical Profile Documentation

Problems Tab

The following items are available for documentation in **Problems** and appear on the **Charge Capture Report (CCR)**. Additional ICD10 Codes* may display to present the surrounding nodes.

Problem	ICD10 Code Choice(s)*
Anogenital warts (disorder)	A63.0 - Anogenital (venereal) warts
History of immunosuppressive therapy (situation)	Z92.25 – Personal history of immunosuppression therapy
History of radiation therapy (situation)	Z92.3 – Personal history of irradiation

Labs, Diagnostic Imaging and Other Services

Lab, Analytes & Panels Additions

- Albumin BF, mg/dL
- Anticardiolipin Ab, IgG, IgM, quan panel
- Anticardiolipin Ab, IgG, quan
- Anticardiolipin Ab, IgM, quan
- Band count, man, cells counted
- CMI1136-ARID1A
- CMI1136-ATM
- CMI1136-BRCA1
- CMI1136-BRCA2
- CMI1136-CHEK1
- CMI1136-CHEK2
- CMI1136-FAT1
- CMI1136-MGMT
- CMI1136-NF2
- CMI1136-PTEN
- CMI1136-RAD51C
- CMI1136-RAD51D
- CMI1136-RB1
- CMI1136-SUFU
- CMI1136-TET2
- CMI1136-TP53
- Copper, RBC, ug/mL
- Delta-ALA urine 24hr panel
- Delta-ALA, random urine
- Delta-ALA, urine, mg/24hr
- Exome CND panel, clinical genes
- Fluoride, serum/plasma, mg/L
- HIV-1/2 ag/ab, 4th gen final interpretation
- JAK2 Exon 12-13 mutation analysis
- JAK2 Exon 12-13 mutation analysis panel
- Polynuclear Abs BF, x 10³/uL
- PSA diagnostic, ng/mL
- SARS-CoV-2 total Ab index, COI
- Total cells BF, x 10⁹/L
- WBC BF, x 10³/uL

Diagnostic Imaging

- Spinal survey w/ IV contrast

Medications

Additions

- CAM2029 invest Subcutaneous
- CUE-101 invest IV
- Durvalumab invest (MEDI4736 invest IV)
- Elitek (Rasburicase IV)
- HBI-2376 invest Oral
- Infliximab (Non-Branded) IV
- KIMMTRAK (Tebentafusp-tebn IV)
- MEDI4736 invest Subcutaneous
- Nemvaleukin alfa invest IV
- Rasburicase IV
- Senaparib invest Oral
- Syringe with needle 27 gauge x 1/2"

Updates

New form available for **NIS793 invest IV**:

- 1050 mg/10.5 mL intravenous solution

New form(s) available for **NUV-422 invest Oral**:

- 50 mg Capsule
- 75 mg Capsule
- 75 mg Tablet
- 100 mg Tablet
- 125 mg Tablet

Regimens

This section does not include clinical trial regimens.

Regimens containing **Infliximab** were updated to reflect the separation of **Infliximab (non-branded)** and **Remicade** to provide to provide clarity during the ordering process.

Additions

Regimen Name
Ado-Trastuzumab emtansine Q21D (Initial Adjuvant Breast)
Epoetin alfa Q7D (Chemotherapy-Induced Anemia)
FOLFIRINOX (Modified) + Bevacizumab BIOSIMILAR Q14D

Regimen Name

Pembrolizumab + Gemcitabine D1,8 + Vinorelbine D1,8 + Liposomal Doxorubicin D1,8 (GVD) Q21D

Polatuzumab vedotin + Rituximab IV BIOSIMILAR + CHP Q21D (6 cycles) fb Rituximab IV BIOSIMILAR Q21D (2 cycles)

Paclitaxel D1,8,15 + Trastuzumab IV BIOSIMILAR + Pertuzumab IV Q21D (Neoadjuvant)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- All Problems
- Amyloidosis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Breast Cancer
- Colon Cancer
- Crohn's Disease
- Lymphoma, Hodgkin (HL)
- Multiple Myeloma (MM)
- Neuroendocrine Tumor, Carcinoid (Parent)
- Pancreatic Cancer
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Rectal Cancer
- Ulcerative Colitis

Removals

- FOLFIRINOX Q14D (Neoadjuvant)

Renames

Previous Name	New Name
Ado-trastuzumab emtansine (Adjuvant) Q21D	Ado-Trastuzumab Emtansine Q21D (Adjuvant Breast Residual Disease)
Carboplatin D1 Q21D (Head and Neck, Bladder)	Carboplatin Q21D (Head and Neck, Bladder, Breast)
Daratumumab + Bortezomib + Melphalan PO D1-4 + Prednisone D1-4 Q28D (Part 2 of 2: Daratumumab only)	Daratumumab IV + Bortezomib + Melphalan PO + Prednisone Q28D (Part 2 of 2: Daratumumab IV only)
Daratumumab + Bortezomib + Melphalan PO D1-4 + Prednisone D1-4 Q42D (Part 1 of 2)	Daratumumab IV + Bortezomib + Melphalan PO + Prednisone Q42D (Part 1 of 2)
Daratumumab + Bortezomib + Melphalan PO D1-4 + Prednisone D1-4 Q42D (Part 1 of 2: C1 Split Dosing)	Daratumumab IV + Bortezomib + Melphalan PO + Prednisone Q42D (Part 1 of 2: C1 Split Dosing)

Daratumumab + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 1 of 2: Induction)	Daratumumab IV + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 1 of 2: Induction)
Daratumumab + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 1 of 2: Induction C1 Split Dosing)	Daratumumab IV + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 1 of 2: Induction C1 Split Dosing)
Daratumumab + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 2 of 2: Post-transplant Consolidation)	Daratumumab IV + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 2 of 2: Post-Transplant Consolidation)
Epoetin alfa Q7D	Epoetin alfa Q7D (CKD)
Fluorouracil (CIV) D1-2 + Leucovorin + Oxaliplatin + Irinotecan (FOLFOXIRI) + Bevacizumab BIOSIMILAR Q14D	FOLFOXIRI + Bevacizumab BIOSIMILAR Q14D
Fluorouracil (CIV) D1-2 + Leucovorin + Oxaliplatin + Irinotecan (FOLFOXIRI) + Bevacizumab Q14D	FOLFOXIRI + Bevacizumab Q14D
Fluorouracil (CIV) D1-2 + Leucovorin + Oxaliplatin + Irinotecan (FOLFOXIRI) Q14D	FOLFOXIRI Q14D
Tumor Lysis Syndrome (TLS) Supportive Care	Tumor Lysis Syndrome (TLS) and Rasburicase Supportive Care
Ustekinumab Initial	Ustekinumab IV (Initial) (Crohn's Disease, Ulcerative Colitis)
Ustekinumab Maintenance	Ustekinumab SQ Q56D (Maintenance) (Crohn's Disease, Ulcerative Colitis)

Research

Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Updates

	Updated Reference Information			
	X	Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 17188	X			

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 18004				<p>Now available for ordering:</p> <ul style="list-style-type: none"> USOR 18004 Part D SGN-LIV14 (D1,8) + Pembrolizumab Q21D
USOR 18095	X	X		<p>Now available for ordering:</p> <ul style="list-style-type: none"> USOR 18095 Neoadjuvant Nivolumab + Gemcitabine D1,8 + Cisplatin Q21D USOR 18095 Neoadjuvant Nivolumab + Gemcitabine D1,8 + Cisplatin D1,8 Q21D USOR 18095 Adjuvant Nivolumab Q28D <p>No longer available for ordering:</p> <ul style="list-style-type: none"> USOR 18095 Neoadjuvant Safety Lead-in BMS-986205 (PO) + Nivolumab + Gemcitabine D1,8 + Cisplatin Q21D USOR 18095 Neoadjuvant Safety Lead-in BMS-986205 (PO) + Nivolumab + Gemcitabine D1,8 + Cisplatin D1,8 Q21D (Split Dose) USOR 18095 Adjuvant Safety Lead-in BMS-986205 (PO) + Nivolumab Q28D USOR 18095 Neoadjuvant Arm B and C BMS-986205 or Placebo (PO) + Nivolumab + Gemcitabine D1,8 + Cisplatin Q21D USOR 18095 Neoadjuvant Arm B and C BMS-986205 or Placebo (PO) + Nivolumab + Gemcitabine D1,8 + Cisplatin D1,8 Q21D (Split Dose)
USOR 18187	X		X	
USOR 18188	X	X		<p>No longer available for ordering:</p> <ul style="list-style-type: none"> USOR 18188 TP-1287 (PO; BID) D1-14 Q21D USOR 18188 TP-1287 (PO; BID) D1-21 Q28D
USOR 19024	X	X	X	<p>Now available for ordering:</p> <ul style="list-style-type: none"> USOR 19024 Phase 2 Part A AMG 510 Monotherapy (PO; Daily)
USOR 19043	X	X	X	
USOR 19118	X	X	X	
USOR 19120	X	X		
USOR 20137	X			

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 20144	X	X	X	<p>Now available for ordering:</p> <ul style="list-style-type: none"> USOR 20144 Brentuximab Vedotin or Placebo + Lenalidomide D1-21 + Rituximab IV Q21 USOR 20144 Brentuximab Vedotin or Placebo + Lenalidomide D1-21 + Rituximab BIOSIMILAR IV Q21D
USOR 20218	X			
USOR 20250	X	X		
USOR 20283	X	X	X	
USOR 20289	X	X	X	
USOR 20297	X	X	X	<p>Now available for ordering:</p> <ul style="list-style-type: none"> USOR 20297 BDC-1001 Monotherapy Q7D USOR 20297 BDC-1001 + Nivolumab Q21D USOR 20297 BDC-1001 + Nivolumab Q14D USOR 20297 BDC-1001 + Nivolumab (odd cycles) Q7D
USOR 20423	X	X	X	<p>Now available for ordering:</p> <ul style="list-style-type: none"> USOR 20423 Tomivosertib or Placebo (PO; BID) + Pemetrexed + Pembrolizumab Q21D USOR 20423 Tomivosertib or Placebo (PO; BID) + Pemetrexed Q21D + Pembrolizumab Q42D USOR 20423 Pemetrexed Pre-Medication
USOR 21183	X	X	X	<p>Now available for ordering:</p> <ul style="list-style-type: none"> USOR 21183 Arm C LY3484356 (PO; Daily) + Abemaciclib (PO; BID) Q28D
USOR 21207		X	X	
USOR 21235				<p>Now available for ordering:</p> <ul style="list-style-type: none"> USOR 21235 NIS793 or Placebo D1,15 + Nab-Paclitaxel D1,8,15 + Gemcitabine D1,8,15 Q28D USOR 21235 NIS793 or Placebo D1 + Nab-Paclitaxel D1,8,15 + Gemcitabine D1,8,15 Q28D <p>No longer available for ordering:</p> <ul style="list-style-type: none"> USOR 21235 NIS793 D1,15 + Nab-Paclitaxel D1,8,15 + Gemcitabine D1,8,15 Q28D USOR 21235 NIS793 D1 + Nab-Paclitaxel D1,8,15 + Gemcitabine D1,8,15 Q28D

	Updated Reference Information			
	Updated Drug Service Order Information		Updated Regimen Instructions	
	X	X		
			Other Changes	
USOR 21281		X	X	
USOR 21321	X	X	X	<p>Now available for ordering:</p> <ul style="list-style-type: none"> USOR 21321 Capsule to Tablet PK Substudy NUV-422 (PO; Daily) Q28D <p>No longer available for ordering:</p> <ul style="list-style-type: none"> USOR 21321 Phase 1 Food Effect NUV-422 (Cycle 1 Day -7) USOR 21321 Surgical Substudy GB NUV-422 (PO; Daily)

Billing & HCPCS Codes

Updates

Medication Name	HCPCS Code
Secukinumab Subcutaneous Pen Injector	J3590 per 150 mg